H
H. A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 224
Citations - 4657
H. A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Metastatic breast cancer. The author has an hindex of 36, co-authored 224 publications receiving 4191 citations.
Papers
More filters
Journal ArticleDOI
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Yung-Jue Bang,Giuseppe Giaccone,Seock-Ah Im,Do Youn Oh,Todd M. Bauer,J. L. Nordstrom,H. Li,Gurunadh Reddy Chichili,Paul A. Moore,S. Hong,S. J. Stewart,J. E. Baughman,R. J. Lechleider,H. A. Burris +13 more
TL;DR: Ex vivo analyses of patient peripheral blood mononuclear cell samples confirmed the ability of margetuximab to support enhanced ADCC compared with trastuzumab, and well-tolerated and has promising single-agent activity.
Journal ArticleDOI
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
J. R. Infante,Leslie A. Fecher,Sujatha Nallapareddy,Michael S. Gordon,Keith T. Flaherty,Donna S. Cox,Douglas J Demarini,Shannon R. Morris,H. A. Burris,Wells A. Messersmith +9 more
TL;DR: The objectives of this study are to define the maximum tolerated dose (MTD), and to evaluate the pharmacokinetics, pharmacodynamics, and response rate of GSK1120212 in advanced solid tumors and lymphoma.
Journal ArticleDOI
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
J. R. Infante,Gerald Steven Falchook,D. P. Lawrence,Jeffrey S. Weber,Richard F. Kefford,Johanna C. Bendell,R. Kurzrock,Geoffrey I. Shapiro,Ragini Kudchadkar,Georgina V. Long,H. A. Burris,K. B. Kim,Arthur Clements,Sheng-Bin Peng,B. Yi,Alicia Allred,Daniele Ouellet,Kiran Patel,Peter F. Lebowitz,Keith T. Flaherty +19 more
TL;DR: GSK212 at 2 mg QD combines safely with GSK436 150 mg BID, no SCC thus far and decreased frequency of rash compared to previous trials of single agent GSK 436 and GSK212, respectively.
Journal ArticleDOI
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies
Michael V. Seiden,H. A. Burris,Ursula A. Matulonis,James B. Hall,Deborah K. Armstrong,J. Speyer,J.D.A. Weber,Franco M. Muggia +7 more
TL;DR: In this population of very heavily pretreated patients with epithelial ovarian and primary peritoneal malignancies, there was no evidence of significant clinical activity when matuzumab was administered as monotherapy.
Journal ArticleDOI
Cabozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study
Robin Kate Kelley,Chris Verslype,Allen Lee Cohn,T.-S. Yang,Wu Chou Su,H. A. Burris,Fadi Braiteh,Nicholas J. Vogelzang,Alexander I. Spira,P. Foster,Yihua Lee,E. Van Cutsem +11 more
TL;DR: Cozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and reductions in AFP, and the most common grade 3/4 adverse events were diarrhea, hand-foot syndrome, and thrombocytopenia.